Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943539 | 1.00 | HTR6 (0.40) | HTR6L3MBTL1GABRA1GABRG2GABRB3 | |
| SCHEMBL124286 | 0.90 | HDAC2 (0.41) | HTR6L3MBTL1 | |
| SCHEMBL3051164 | 0.89 | HTR6 (0.46) | HTR6L3MBTL1GABRA1GABRG2GABRB3 | |
| SCHEMBL23330894 | 0.85 | L3MBTL1 (0.43) | HTR6L3MBTL1BCHEMKNK1BRD4 | |
| SCHEMBL23330904 | 0.84 | MAP2K4 (0.41) | HTR6L3MBTL1 | |
| SCHEMBL22749553 | 0.84 | HTR6 (0.43) | HTR6L3MBTL1GABRA1GABRG2GABRB3 | |
| SCHEMBL18418500 | 0.84 | HTR6 (0.40) | HTR6L3MBTL1GABRA1GABRG2GABRB3 | |
| SCHEMBL23330476 | 0.84 | HTR6 (0.40) | HTR6L3MBTL1GABRA1GABRG2GABRB3 | |
| SCHEMBL29364313 | 0.83 | L3MBTL1 (0.41) | HTR6L3MBTL1BCHEBRD4MEN1 | |
| SCHEMBL24721572 | 0.83 | HTR6 (0.40) | HTR6L3MBTL1GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| CN-112724127-B | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| CN-114829357-A | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2022-07-29 | — | — | CN | disclosed |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | PFIZER INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180222862-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2018-08-09 | — | — | US | disclosed |
| EP-3334733-A1 | 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Pfizer Inc (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9873690-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | PFIZER INC (US) | 2018-01-23 | — | — | US | disclosed |
| WO-2017025868-A1 | 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PFIZER INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-3119763-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Iteos Therapeutics (BE) | 2017-01-25 | — | — | EP | disclosed |
| US-20160272628-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PFIZER INC. | 2016-09-22 | — | — | US | disclosed |
| WO-2015140717-A9 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-03-24 | — | — | WO | disclosed |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
| WO-2015140717-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | HTR6 2155/4885L3MBTL1 1271/4885GABRA1 4531/4885 |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | STING1, CGAS, IRF3 | HTR6 1679/4885L3MBTL1 4540/4885GABRA1 1095/4885 |
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | HIPK1, PDXK, IP6K1 | HTR6 423/4885L3MBTL1 2183/4885GABRA1 3058/4885 |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 47/4885L3MBTL1 3366/4885GABRA1 4812/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HTR6 2155/4885L3MBTL1 1271/4885GABRA1 4531/4885 |
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | TDO2, IDO1, IDO2 | HTR6 42/4885L3MBTL1 3235/4885GABRA1 4775/4885 |
| US-20180222862-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 49/4885L3MBTL1 3522/4885GABRA1 4763/4885 |
| US-20160272628-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 49/4885L3MBTL1 3522/4885GABRA1 4763/4885 |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | HTR6 423/4885L3MBTL1 2008/4885GABRA1 3239/4885 |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, IP6K1, PDXK | HTR6 399/4885L3MBTL1 4204/4885GABRA1 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.